AR068822A1 - Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida, torta farmaceutica, proceso - Google Patents

Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida, torta farmaceutica, proceso

Info

Publication number
AR068822A1
AR068822A1 ARP080104055A ARP080104055A AR068822A1 AR 068822 A1 AR068822 A1 AR 068822A1 AR P080104055 A ARP080104055 A AR P080104055A AR P080104055 A ARP080104055 A AR P080104055A AR 068822 A1 AR068822 A1 AR 068822A1
Authority
AR
Argentina
Prior art keywords
methyl
pharmaceutical
propenamide
indol
phenyl
Prior art date
Application number
ARP080104055A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40005335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR068822(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR068822A1 publication Critical patent/AR068822A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Una composicion farmacéutica, la cual comprende: (a) N-hidroxi-3-[4-[[[(2-(2-metil-1H-indol-3-il)-etil]-amino]-metil]-fenil]-2E-2-propenamida, o una sal farmacéuticamente aceptable de la misma; (b) un regulador del pH o un componente regulador del pH; (c) un agente de volumen. Reivindicacion 2: La composicion de la reivindicacion 1, la cual comprende además un quelante/antioxidante. Reivindicacion 3: La composicion de la reivindicacion 1, en donde el agente de volumen mencionado se selecciona a partir de sacarosa, trehalosa, dextrano, y HPbCD. Reivindicacion 4: La composicion de la reivindicacion 2, en donde el quelante/antioxidante mencionado es EDTA disodica.
ARP080104055A 2007-09-20 2008-09-18 Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida, torta farmaceutica, proceso AR068822A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97383007P 2007-09-20 2007-09-20

Publications (1)

Publication Number Publication Date
AR068822A1 true AR068822A1 (es) 2009-12-09

Family

ID=40005335

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104055A AR068822A1 (es) 2007-09-20 2008-09-18 Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida, torta farmaceutica, proceso

Country Status (20)

Country Link
US (1) US20100331387A1 (es)
EP (1) EP2205222A1 (es)
JP (1) JP2010540445A (es)
KR (1) KR20100059887A (es)
CN (1) CN101801345A (es)
AR (1) AR068822A1 (es)
AU (1) AU2008302273A1 (es)
BR (1) BRPI0817118A2 (es)
CA (1) CA2696914A1 (es)
CL (1) CL2008002786A1 (es)
CO (1) CO6270207A2 (es)
EC (1) ECSP10010039A (es)
GT (1) GT201000062A (es)
MA (1) MA31744B1 (es)
MX (1) MX2010002970A (es)
PE (1) PE20090706A1 (es)
RU (1) RU2010115262A (es)
TN (1) TN2010000097A1 (es)
TW (1) TW200930416A (es)
WO (1) WO2009039226A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017167837A1 (en) * 2016-03-31 2017-10-05 Midatech Ltd. Cyclodextrin-panobinostat adduct

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
ME00294B (me) * 2003-07-23 2011-05-10 Bayer Pharmaceuticals Corp Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti
WO2005013958A1 (en) * 2003-08-07 2005-02-17 Novartis Ag Histone deacetylase inhibitors as immunosuppressants
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
CA2674604A1 (en) * 2007-01-10 2008-07-17 Novartis Ag Formulations of deacetylase inhibitors
MX2009008584A (es) * 2007-02-15 2009-08-18 Novartis Ag Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.

Also Published As

Publication number Publication date
CL2008002786A1 (es) 2009-05-15
CA2696914A1 (en) 2009-03-26
CN101801345A (zh) 2010-08-11
KR20100059887A (ko) 2010-06-04
TW200930416A (en) 2009-07-16
JP2010540445A (ja) 2010-12-24
RU2010115262A (ru) 2011-10-27
MX2010002970A (es) 2010-04-01
US20100331387A1 (en) 2010-12-30
MA31744B1 (fr) 2010-10-01
ECSP10010039A (es) 2010-04-30
PE20090706A1 (es) 2009-07-15
CO6270207A2 (es) 2011-04-20
WO2009039226A1 (en) 2009-03-26
GT201000062A (es) 2012-03-30
EP2205222A1 (en) 2010-07-14
AU2008302273A1 (en) 2009-03-26
TN2010000097A1 (en) 2011-09-26
BRPI0817118A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
WO2008100985A3 (en) Combination of lbh589 with other therapeutic agents for treating cancer
AR061298A1 (es) Sales de n-hidroxi -3- [4- [ [ [2- (2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2- propenamida.composciones farmaceuticas.
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
PE20090211A1 (es) Inhibidores de las iap
PE20151953A1 (es) Composicion farmaceutica que comprende bis-(monoetanolamina) de acido 3'-[(2z)-[1-(3, 4-dimetilfenil)-1, 5-dihidro-3-metil-5-oxo-4h-pirazol-4-ilideno] hidrazino]-2'-hidroxi-[1, 1'-bifenil]-3-carboxilico
RU2012123372A (ru) Гетероциклические модуляторы транспортеров атф-связывающей кассеты
CY1115710T1 (el) Ρευστο παρασκευασμα που περιλαμβανει ενα συμπλοκο πιμοβενδανης και κυκλοδεξτρινης
HRP20090340T1 (en) 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
SV2009002900A (es) Diarilurea para el tratamiento de hipertension pulmonar
NO20042361L (no) Form av 3-[(2{4-(Heksyloksykarbonylamino-imino-metyl)-fenylami no]-metyl}-1- metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]propionsyreetylester for oral
BRPI0719393B8 (pt) composição farmacêutica
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
WO2012147107A3 (en) Novel & improved processes for preparing indoline derivatives and its pharmaceutical composition
MX2010004501A (es) Inhibidor de la proteina de activacion de 5-lipoxigenasa (plap).
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
NO20090136L (no) Fremgangsmate for fremstilling av salter av N-hydroksy-3-[4-[[[2-(2-metyl-1H-1ln-dol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid
CO6612204A2 (es) Nuevas composiciones de 1-(2(2.4 dimetil-fenilsulfanil)- fenil) piperazina
AR064072A1 (es) Combinacion para el tratamiento de una enfermedad proliferativa
AR068822A1 (es) Composiciones farmaceuticas liofilizadas que comprenden n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida, torta farmaceutica, proceso
NO20092695L (no) Profylaktisk eller terapeutisk middel for alopeki
MY145122A (en) Phenylacetic acid derivatives as cox-2 inhibitors
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
NO20074505L (no) Partikkel og preparat inneholdende partikkelen
AR041475A1 (es) Producto de acoplamiento entre la triptamina y un alfa-amino-acido, su proceso de preparacion asi como su aplicacion en el campo de la neurocosmetica

Legal Events

Date Code Title Description
FB Suspension of granting procedure